Internal Medicine, Infectious Disease · Houston, TX
NPI
1235233651
Since 2006
Specialty
Internal Medicine, Infectious Disease
Code 207RI0200X
Group practices
1
Medicare group memberships
Hospitals
1
Hospital affiliations
7777 Southwest Fwy, Suite 610
Houston, TX, 77074
Phone (713) 339-9949
Groups this clinician bills Medicare through
Medicare paid, 2024
$489K
249,241 services
Medicare patients, 2024
142
Average age 72
Drug cost, 2024
$2.1M
1,815 prescriptions
Company payments, 2025
$1,783
From 14 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Shahe E Vartivarian was code J0692 (injection, cefepime hydrochloride, 500 mg), 3,626 times for 20 patients. In total Shahe E Vartivarian billed 249,241 services in 57 codes, and Medicare paid $489K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2024-05-22.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J0692 Injection, cefepime hydrochloride, 500 mg | Office | 3,626 | 20 | $0.98 | $3,571 |
| J3370 Injection, vancomycin hcl, 500 mg | Office | 1,778 | 17 | $1.75 | $3,111 |
| 96521 Chemotherapy | Office | 993 | 39 | $96.70 | $96K |
| 99213 Office E&M - Established | Office | 787 | 85 | $72.09 | $57K |
| 96365 Intravenous Infusion, Hydration | Office | 468 | 20 | $49.60 | $23K |
| 99232 Hospital E&M - Subsequent | Facility | 209 | 29 | $62.29 | $13K |
| 99183 Hyperbaric Oxygen | Facility | 149 | 11 | $84.27 | $13K |
| 99231 Hospital E&M - Subsequent | Facility | 130 | 26 | $39.46 | $5,130 |
| 11042 Debridement | Facility | 100 | 15 | $48.98 | $4,898 |
| 99204 Office E&M - New | Office | 36 | 36 | $130.10 | $4,684 |
| 99214 Office E&M - Established | Office | 33 | 23 | $99.19 | $3,273 |
By year: 2022 $390K for 99,520 services; 2023 $379K for 100,406 services; 2024 $489K for 249,241 services.
Medicare prescription drug claims, 2024
In 2024, the drug Shahe E Vartivarian prescribed most often to Medicare patients was Biktarvy (Bictegrav/Emtricit/Tenofov Ala), with 193 prescriptions and refills. In total Shahe E Vartivarian wrote 1,815 Medicare prescriptions that cost $2.1M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Biktarvy Bictegrav/Emtricit/Tenofov Ala | 193 | 193 | 25 | $820K |
| Levofloxacin Generic | 131 | 149 | 51 | $2,429 |
| Amoxicillin-Clavulanate Potass Amoxicillin/Potassium Clav | 118 | 126 | 40 | $2,185 |
| Fluconazole Generic | 102 | 109 | 39 | $2,741 |
| Doxycycline Hyclate Generic | 69 | 69 | 25 | $1,028 |
| Daptomycin Generic | 67 | 67 | Under 11 | $22K |
| Meropenem Generic | 66 | 66 | Under 11 | $9,216 |
| Emtricitabine-Tenofovir Disop Emtricitabine/Tenofovir (Tdf) | 64 | 64 | Under 11 | $6,560 |
| Linezolid Generic | 52 | 52 | 21 | $4,353 |
| Cefpodoxime Proxetil Generic | 51 | 53 | 18 | $4,709 |
| Metronidazole Generic | 38 | 38 | 28 | $718 |
| Ertapenem Ertapenem Sodium | 34 | 34 | Under 11 | $11K |
| Symtuza Darunavir/Cob/Emtri/Tenof Alaf | 34 | 42 | Under 11 | $197K |
| Ceftriaxone Ceftriaxone Sodium | 34 | 34 | Under 11 | $1,149 |
| Nystatin Generic | 34 | 36 | 21 | $556 |
Brand drugs: 491 claims; generic drugs: 1,324 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Shahe E Vartivarian $1,783 ($1,783 in general payments such as food, travel and fees) from 14 companies. The largest payer was Cumberland Pharmaceuticals, Inc. with $316.
| Company | Payments | Amount |
|---|---|---|
| Cumberland Pharmaceuticals, Inc. CPIX | 21 | $316 |
| ViiV Healthcare Company GSK | 13 | $284 |
| Gilead Sciences, Inc. GILD | 12 | $212 |
| Paratek Pharmaceuticals, Inc. | 12 | $211 |
| Abbvie Inc. ABBV | 13 | $179 |
| Smith+Nephew, Inc. SNN | 2 | $169 |
| EMD Serono, Inc. MRK.DE | 2 | $79.93 |
| Merck Sharp & Dohme LLC MRK | 3 | $66.75 |
| Shionogi Inc 4507.T | 3 | $64.46 |
| Aimmune Therapeutics, Inc. | 2 | $58.31 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.